Table 3.
Primary and secondary outcomes
| Outcome | Event rate per 1000 patient-years at risk
|
Unadjusted analysis hazard ratio (95% CI) | Adjusted analysisa hazard ratio (95% CI) | |
|---|---|---|---|---|
| Statin | Control | |||
| Primaryb | 62.6 | 102.7 | 0.51 (0.47–0.57) | 0.51 (0.46–0.57) |
| Myocardial infarction | 10.5 | 12.6 | 0.82 (0.67–1.01) | 0.82 (0.65–1.04) |
| Stroke | 4.7 | 6.4 | 0.68 (0.52–0.89) | 0.72 (0.54–0.96) |
| Heart failure | 24.7 | 29.3 | 0.82 (0.69–0.97) | 0.83 (0.69–0.99) |
| Acute renal failure | 5.5 | 6.1 | 0.84 (0.61–1.17) | 0.89 (0.63–1.27) |
| Dialysis | 6.7 | 9.9 | 0.81 (0.65–1.02) | 0.66 (0.52–0.86) |
| Death | 31.6 | 89.0 | 0.28 (0.24–0.31) | 0.27 (0.24–0.31) |
| Renal hospitalization | 14.5 | 20.3 | 0.73 (0.59–0.90) | 0.69 (0.55–0.87) |
| Malignant hypertension | 2.0 | 10.7 | 0.37 (0.14–1.03) | 0.18 (0.05–0.60) |
| Revascularizationc | 68.9 | 64.9 | 1.26 (1.09–1.46) | 1.08 (0.91–1.27) |
a
Adjusted for demographic characteristics, cardiovascular risk factors, comorbidities, measures of health-care utilization, screening, and medications.
b
Defined as first occurrence of myocardial infarction, stroke, heart failure, acute renal failure, dialysis, or death.
c
Coronary, cerebrovascular, and peripheral revascularization procedures.